Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28183003 | 0.97 | SIGMAR1 (0.43) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL716430 | 0.78 | SIGMAR1 (0.48) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL17086068 | 0.75 | — | — | |
| SCHEMBL3836071 | 0.74 | SIGMAR1 (0.45) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL22341229 | 0.74 | SIGMAR1 (0.68) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL629800 | 0.74 | SIGMAR1 (0.68) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL22838527 | 0.74 | SIGMAR1 (0.68) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL22520986 | 0.74 | SIGMAR1 (0.68) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL6247127 | 0.74 | SIGMAR1 (0.45) | SIGMAR1EPHX1CYP1A2KDM1AMAOA | |
| SCHEMBL19355233 | 0.74 | SIGMAR1 (0.68) | SIGMAR1EPHX1CYP1A2KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024177858-A1 | PROCESSES FOR REDUCING ENVIRONMENTAL AVAILABILITY OF ENVIRONMENTAL POLLUTANTS | ALBEMARLE CORPORATION (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-01-19 | — | — | US | disclosed |
| WO-2015138895-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| EP-1454958-B1 | LACTIC ACID POLYMER COMPOSITION AND MOLDED OBJECT THEREOF | NEW JAPAN CHEM CO LTD (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20050001349-A1 | Lactic acid polymer composition and molded object thereof | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1454958-A1 | LACTIC ACID POLYMER COMPOSITION AND MOLDED OBJECT THEREOF | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-5973076-A | MOLDING; CONTROLLING TEMPERATURE IN PRESENCE OF AN AMIDE COMPOUND | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0776933-B1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEM CO LTD (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0776933-A1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | SIGMAR1 1174/4885EPHX1 4232/4885CYP1A2 1361/4885 |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | SIGMAR1 3396/4885EPHX1 2331/4885CYP1A2 311/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | SIGMAR1 3396/4885EPHX1 2331/4885CYP1A2 311/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | SIGMAR1 3396/4885EPHX1 2331/4885CYP1A2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.